Novavax has signed a memorandum of understanding (MOU) with the vaccine alliance, Gavi, to provide 1.1 billion doses of its recombinant protein-based COVID-19 vaccine, NVX-CoV2373, for...
Pfizer’s Covid-19 vaccine greatly reduces virus transmission, shedding light on one of the biggest questions of the global effort to quash the pandemic.
Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of the company's Covid-19 vaccine candidate NVX-CoV2373 for the COVAX...
Analysis shows certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed Credit: Photo by Robert Hood / Fred...
Novavax has signed a deal to provide 1.1 billion doses of its COVID-19 vaccine to the COVAX global initiative.
Japan's Incredibly Shrinking Population Is A Big Problem Submitted by Ethen Kim Lieser of 19FortyFive.com, Science and Tech Editor who has held posts at Google, The...
A study of global trials of Fujifilm Holdings Corp.’s Avigan suggests the antiviral drug has little benefit for Covid-19 patients once their symptoms become serious.
With the vaccines now being administered at sites around the US, it is important to address misinformation surrounding the effort.
With a third of adults saying they likely won't get the vaccine and 20% of the population under 16, the US has a herd immunity math...
COVID-19 has already proved to be a digital accelerant for the pharmaceutical industry, sparking new ideas into life The post No cooling off for pharma digital...
GlaxoSmithKline is expanding a coronavirus antibody collaboration with US biotech Vir, to include potential therapies for flu and The post GSK expands coronavirus antibody tie-up to...
The temporary suspensions affect the Phase I/II HGB-206 trial, an ongoing, open-label study designed to evaluate the efficacy and safety of LentiGlobin gene therapy for sickle...
The US has a herd immunity math problem, with a COVID-19 vaccine not yet approved for children under 16 and a third of adults saying they...
Graphene based COVID tests are quick and robust.
AstraZeneca announced yesterday that the World Health Organization (WHO) has granted an Emergency Use Listing (EUL) for its COVID-19 vaccine. The authorization permits the global use...
The U.S. Food and Drug Administration approved Pfizer Inc.'s supplemental Biologics License Application for Panzyga to treat adult patients with a rare neurological disease of the...
Healthware Group has partnered with the National Cancer Institute of Naples in Italy to develop and roll out The post Healthware and Italian cancer institute partner...
German Nursing Home Whistleblower: "Elderly Dying After COVID Vaccine" Via 21stCenturyWire.com, Since the public release of the controversial mRNA vaccine, many disturbing reports of adverse reactions...
A Covid-19 vaccine candidate developed by Sanofi and U.S. group Translate Bio “will not be ready this year,” the French drugmaker’s chief executive told Le Journal...
Sanofi’s CEO, Paul Hudson, said that the mRNA-based COVID-19 vaccine developed with Translate Bio will not be ready this year
G1 Therapeutics announced that the US Food and Drug Administration (FDA) has approved its COSELA drug as a first-of-its-kind treatment for patients with extensive-stage small cell...
Regeneron announced that the US Food and Drug Administration (FDA) has approved its Evkeeza antibody as a first-of-its-kind treatment for adult and pediatric patients with extremely...
Mobile laboratory for rapid detection of SARS-CoV-2 for Africa Credit: Dr Ahmed Abd El Wahed The PCR test is the most accurate tool to identify SARS-CoV-2....
Credit: Rayne Zaayman-Gallant/EMBL In the early days of the COVID-19 pandemic, it was established that SARS-CoV-2 infects cells by binding to the human protein ACE2, which...
Clinical trial to explore the potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19 in biologically aged individuals. Credit: Deep...
Chile made a strong case for price reductions, cut deals with multiple providers and participated in trials for early access.
CNBC Transcript: Johnson & Johnson Chairman & CEO Alex Gorsky speaks with Meg Tirrell live during CNBC’s Healthy Returns Spotlight today on the company’s one-shot coronavirus...
When the pandemic heated up early last year, the UK Biobank set out to urgently gather data on COVID-19 diagnostic tests, deaths, and hospitals episodes, such...
Despite advances in understanding the genetic underpinning of many diseases, roadblocks to therapeutic development remain. The post Human Genome Project at 20 appeared first on Clinical...
Dutch biotech InteRNA Technologies has raised €18.5 million ($22 million) in second-round financing as it prepares to start The post Cash round sets up trial of...